Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Liquid Metformin PK and Bioavailability Study
NCT07300020Phase 1Not yet recruiting
- Sponsor
- Aspargo Laboratories
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Aspargo Laboratories. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07300020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300020.